RxDoctor Payments Data

Rakesh Malik, MD

Internal Medicine · Germantown, MDNPI 1750341533

Payments from drug & device makers

$430in general payments, 2019–2025

Across 10 payments — averaging $42.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$170
  • Philips North America LLC$113
  • Inspire Medical Systems, Inc.$76
  • Sumitomo Pharma America, Inc.$25
  • GSK$17
  • Boehringer Ingelheim$15
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$41597%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$430 in reported general payments places this provider in the 60th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$597,455
Medicare patients
1,613
Services billed
5,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$37,864
EliquisApixaban31$36,662
MyrbetriqMirabegron26$28,104
JanumetSitagliptin Phos/Metformin Hcl20$27,070
XareltoRivaroxaban18$27,005
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$21,048
Breo ElliptaFluticasone/Vilanterol14$15,706
LinzessLinaclotide15$13,687
TrulancePlecanatide22$13,612
Jentadueto XrLinagliptin/Metformin Hcl11$13,285
Mesalamine DrMesalamine11$5,694
Rosuvastatin Calcium112$3,988
Diclofenac Sodium48$2,856
Carbamazepine11$2,200
Ezetimibe45$2,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$17$53,57045 claims
AbbVieLinzess$170$13,68715 claims
Boehringer IngelheimJentadueto Xr$15$13,28511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Germantown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →